Lumasiran
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Hyperoxaluria Type 1
Conditions
Primary Hyperoxaluria Type 1, Primary Hyperoxaluria
Trial Timeline
Jan 21, 2020 → Jun 23, 2025
NCT ID
NCT04152200About Lumasiran
Lumasiran is a phase 3 stage product being developed by Alnylam Pharmaceuticals for Primary Hyperoxaluria Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT04152200. Target conditions include Primary Hyperoxaluria Type 1, Primary Hyperoxaluria.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04125472 | Pre-clinical | Completed |
| NCT04152200 | Phase 3 | Completed |
| NCT03905694 | Phase 3 | Completed |
| NCT03350451 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Hyperoxaluria Type 1